BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36624662)

  • 1. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
    Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
    J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based simulation to support the extended dosing regimens of atezolizumab.
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
    Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
    J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
    Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
    Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
    Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
    Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.
    Marolleau S; Mogenet A; Boeri C; Hamimed M; Ciccolini J; Greillier L
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1795-1803. PubMed ID: 38011601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
    Puszkiel A; Bianconi G; Pasquiers B; Balakirouchenane D; Arrondeau J; Boudou-Rouquette P; Bretagne MC; Salem JE; Declèves X; Vidal M; Kramkimel N; Guegan S; Aractingi S; Huillard O; Alexandre J; Wislez M; Goldwasser F; Blanchet B
    Br J Cancer; 2024 May; 130(11):1866-1874. PubMed ID: 38532102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
    Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Lee JB; Broadwell A; Fan Y; Hu C; Adedokun OJ; Chakravarty SD; Zhou H; Xu Z; Leu JH
    Clin Ther; 2022 Mar; 44(3):457-464.e2. PubMed ID: 35183373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
    Liu SN; Marchand M; Liu X; Ingle G; Maiya V; Graupner V; Elze MC; Chan P; Hsu JC; Lin A; Vadhavkar S; Wu B; Bruno R
    J Clin Pharmacol; 2022 Nov; 62(11):1393-1402. PubMed ID: 35576521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
    Liu SN; Lu T; Jin JY; Li C; Girish S; Melnikov F; Badovinac Crnjevic T; Machackova Z; Restuccia E; Kirschbrown WP
    J Clin Pharmacol; 2021 Aug; 61(8):1096-1105. PubMed ID: 33719071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
    Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
    Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
    Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
    J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.